Oral CBD Did Not Significantly Reduce Seborrheic Dermatitis in Parkinson's Patients in Small Trial | Research

The takeaway

A 16-day randomized trial of oral CBD in Parkinson's patients found no statistically significant reduction in seborrheic dermatitis, though the CBD group trended toward improvement while the placebo group trended toward worsening.

Dermatologists and neurologists treating Parkinson's patients; researchers designing CBD trials for skin conditions.

p = .07 between-group difference, with CBD trending toward improvement and placebo toward worsening

What the researchers found

CBD treatment did not significantly reduce seborrheic dermatitis severity or presence. However, the CBD group showed a non-significant trend toward improvement (risk ratio 0.69 for post vs pre) while the placebo group showed a non-significant trend toward worsening (risk ratio 1.20). The between-group difference approached significance (p = .07).

Why it matters

Seborrheic dermatitis affects up to 59% of people with Parkinson's disease and is difficult to treat. While this trial was too small and short to detect a clear effect, the opposing trends between CBD and placebo groups suggest CBD may have dermatological effects worth investigating in larger studies.

The numbers in context

53 patients (27 placebo, 26 CBD). CBD dose: 2.5 mg/kg/day for 16 days. CBD group post vs pre risk ratio: 0.69 (95% CI: 0.41-1.18, p = .15). Placebo group: 1.20 (95% CI: 0.88-1.65, p = .26). Between-group difference: p = .07.

How the study worked

Randomized (1:1), parallel, double-blind, placebo-controlled trial. 53 Parkinson's patients (27 placebo, 26 CBD) received 16 days of oral CBD-rich cannabis extract (2.5 mg/kg/day CBD with 0.08 mg/kg/day THC) or placebo. Facial photographs were scored independently using the SEDASI scale by blinded reviewers.

What this study cannot tell us

Substantially underpowered for the dermatological outcome. Treatment duration of only 16 days may be insufficient for skin conditions. Baseline seborrheic dermatitis severity was low in both groups, creating a floor effect. The oral route may not deliver adequate concentrations to skin.

How to read the evidence

Preliminary: rigorous RCT design but substantially underpowered for the dermatological outcome, with short treatment duration and low baseline severity.

When this study was published

2024 publication.

The bigger picture

CBD has demonstrated anti-inflammatory and sebum-regulating properties in preclinical studies. This trial was designed primarily to test CBD's effects on Parkinson's motor symptoms, with seborrheic dermatitis as a secondary outcome, explaining why it was underpowered for this skin condition.

Questions still open

Would a longer treatment duration or higher dose produce significant skin improvements? Would topical CBD application be more effective than oral for seborrheic dermatitis? Is the near-significant between-group difference (p = .07) a real signal or statistical noise?

Common questions

Why was this study underpowered?

The trial was originally designed to test CBD for Parkinson's motor symptoms. Seborrheic dermatitis was a secondary outcome, and the 53-patient sample was not large enough to detect the likely small-to-moderate effect of CBD on skin inflammation.

Does this mean CBD does not help skin conditions?

Not necessarily. The opposing trends (CBD improved, placebo worsened) and the near-significant between-group difference suggest a possible effect that a larger, longer, adequately powered study could confirm or rule out.

Read the original research

Oral Cannabidiol for Seborrheic Dermatitis in Patients With Parkinson Disease: Randomized Clinical Trial.

JMIR dermatology, 7, e49965

View on PubMed ↗Publisher’s paper ↗

Citation

Weber, Isaac; Zagona-Prizio, Caterina; Sivesind, Torunn E; Adelman, Madeline; Szeto, Mindy D; Liu, Ying; Sillau, Stefan H; Bainbridge, Jacquelyn; Klawitter, Jost; Sempio, Cristina; Dunnick, Cory A; Leehey, Maureen A; Dellavalle, Robert P. (2024). Oral Cannabidiol for Seborrheic Dermatitis in Patients With Parkinson Disease: Randomized Clinical Trial.. JMIR dermatology, 7, e49965. https://doi.org/10.2196/49965